Previous 10 | Next 10 |
Karyopharm Therapeutics (NASDAQ: KPTI ) slips 1% premarket on heels of Phase 2b data on XPOVIO (selinexor), combined with low-dose dexamethasone, in patients with heavily pretreated triple class refractory multiple myeloma (MM). The results were just published in the onlin...
-- XPOVIO was Recently Approved by the FDA for the Treatment of Patients with Multiple Myeloma whose Disease is Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and an Anti-CD38 Monoclonal Antibody -- -- In STORM, XPOVIO Achieved a 26% Overall Response Rate...
NEW YORK, NY / ACCESSWIRE / August 13, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ:KPTI) of the September 23, 2019 deadline to seek the role ...
Karyopharm Therapeutics Inc. (KPTI) Q2 2019 Earnings Conference Call August 6, 2019 8:30 A.M. ET Company Participants Ian Karp - Vice President, Investor and Public Relations Dr. Michael Kauffman - Chief Executive Officer Perry Monaco - Senior Vice President, Sales Mike Mason -...
Karyopharm (NASDAQ: KPTI ) Q2 results : License and other revenue: $9.5M (-52%). Net loss: ($43.4M), loss/share: ($0.71). More news on: Karyopharm Therapeutics Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
SAN FRANCISCO, CA / ACCESSWIRE / July 30, 2019 / Hagens Berman Sobol Shapiro LLP alerts investors in Karyopharm Therapeutics Inc.’s (NASDAQ: KPTI) April 28, 2017 and May 7, 2018 public offerings to the firm’s ongoing investigation into possible securities law violation...
NEWTON, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, announced today that it will report second quarter 2019 financial results on Tuesday, August 6, 2019. Karyopharm's management team will host a conference ...
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between March 2, 2017 and February 22, 2019, and the Securities Exchange Act ...
Lately, Karyopharm Therapeutics ( KPTI ) has been one of the top trending tickers in the healthcare industry. The stock is up by 55.65% since July 1. Ironically, the stock is down by 5.98% in 2019 YTD. Still, this has not reduced the overall interest in the stock, from investors as well as ana...
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI ) investors concerning the Company and its officers’ possible violations of federal sec...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 PR Newswire -- Conference Call Scheduled for Tuesday, August 6, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasd...
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...
Karyopharm to Participate at the Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...